Trump announces drug pricing deal with Regeneron, completing White House's 17-deal target

President Trump announced a drug‑pricing agreement with Regeneron Pharmaceuticals, marking the final deal in the administration's goal of securing 17 pricing arrangements.

The agreement is intended to curb the cost of Regeneron's medicines and reflects the White House's broader push to address high drug prices across the industry.

The newsletter also noted other policy topics, including a move to reclassify medical marijuana and resistance from legislators in two states to proposals that would limit prescription‑drug rate‑setting boards.

These developments were highlighted in Ed Silverman's Pharmalittle column, which blends industry news with commentary on upcoming events and lifestyle suggestions for readers.